Drug · Other
Filgrastim
CI-DRUG-00000683Explore in graph →CHEMBL1201567 Approved
Regulatory
Approvals (34)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as FILRA (DIN 02556545) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Sep 16, 2025 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as FILRA (DIN 02556537) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Sep 16, 2025 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as NYPOZI (DIN 02520990) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jan 24, 2024 | health-canada-dpd |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 14 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 47 | 24 | 132 | 763 | 34 | CA, EU, US | Feb 20, 1991 | 1988-03 |
| Leukemia | Approved | Phase 4 | 16 | 9 | 24 | 205 | 2 | US | Feb 20, 1991 | 1993-01 |
| Malignant Breast Neoplasm | Phase4 | Phase 4 | 1 | 1 | 12 | 72 | 0 | — | — | 1991-11 |
| Non-Hodgkin Lymphoma | Phase3 | Phase 3 | 7 | 3 | 10 | 93 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (767)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma |